These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 12647609)

  • 1. A pharmacoeconomic evaluation of major depressive disorder.
    Casciano R
    Manag Care Interface; 2003; Suppl B():16-21. PubMed ID: 12647609
    [No Abstract]   [Full Text] [Related]  

  • 2. A multinational pharmacoeconomic evaluation of acute major depressive disorder (MDD): a comparison of cost-effectiveness between venlafaxine, SSRIs and TCAs.
    Doyle JJ; Casciano J; Arikian S; Tarride JE; Gonzalez MA; Casciano R
    Value Health; 2001; 4(1):16-31. PubMed ID: 11704969
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Danish cost-effectiveness model of escitalopram in comparison with citalopram and venlafaxine as first-line treatments for major depressive disorder in primary care.
    Sørensen J; Stage KB; Damsbo N; Le Lay A; Hemels ME
    Nord J Psychiatry; 2007; 61(2):100-8. PubMed ID: 17454724
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness evaluation in Sweden of escitalopram compared with venlafaxine extended-release as first-line treatment in major depressive disorder.
    Nordström G; Danchenko N; Despiegel N; Marteau F
    Value Health; 2012; 15(2):231-9. PubMed ID: 22433753
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A cost-effectiveness model of escitalopram, citalopram,and venlafaxine as first-line treatment for major depressive disorder in Belgium.
    Demyttenaere K; Hemels ME; Hudry J; Annemans L
    Clin Ther; 2005 Jan; 27(1):111-24. PubMed ID: 15763612
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Venlafaxine-associated serotonin syndrome and manic episode in a geriatric depressive patient.
    Liau CH; Shen WW; Su KP
    Psychiatry Clin Neurosci; 2006 Feb; 60(1):121-2. PubMed ID: 16472373
    [No Abstract]   [Full Text] [Related]  

  • 7. Comparison study of venlafaxine and paroxetine for the treatment of depression in elderly Chinese inpatients.
    Hwang JP; Yang CH; Tsai SJ
    Int J Geriatr Psychiatry; 2004 Feb; 19(2):189-90. PubMed ID: 14758586
    [No Abstract]   [Full Text] [Related]  

  • 8. Pharmacoeconomic studies of antidepressants: focus on venlafaxine.
    Woods SW
    Depress Anxiety; 2000; 12 Suppl 1():102-9. PubMed ID: 11098423
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adequacy of venlafaxine dose prescribing in major depression and hospital resources implications.
    Vanoli A; Lane C; Harrison C; Steen N; Young A
    J Psychopharmacol; 2008 Jun; 22(4):434-40. PubMed ID: 18635723
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of pharmacoeconomic modeling in depression management by a health plan.
    Watkins JB
    Manag Care Interface; 2003; Suppl B():22-6. PubMed ID: 12647610
    [No Abstract]   [Full Text] [Related]  

  • 11. Cost effectiveness of venlafaxine compared with generic fluoxetine or generic amitriptyline in major depressive disorder in the UK.
    Lenox-Smith A; Greenstreet L; Burslem K; Knight C
    Clin Drug Investig; 2009; 29(3):173-84. PubMed ID: 19243210
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness measures of major depressive disorder in pharmacoeconomic evaluations.
    Casciano R
    Manag Care Interface; 2003; Suppl B():14-5. PubMed ID: 12647608
    [No Abstract]   [Full Text] [Related]  

  • 13. Choosing a second generation antidepressant for treatment of major depressive disorder.
    Lester H; Gilbody S
    BMJ; 2012 Feb; 344():e1014. PubMed ID: 22334542
    [No Abstract]   [Full Text] [Related]  

  • 14. Olanzapine plus venlafaxine in treatment-resistant depression.
    Devarajan S; Dursun SM
    J Psychopharmacol; 2005 Jul; 19(4):434-5. PubMed ID: 15983004
    [No Abstract]   [Full Text] [Related]  

  • 15. Asystole during electroconvulsive therapy in an elderly woman treated concomitantly with venlafaxine.
    Lyons JE; Symon J
    Aust N Z J Psychiatry; 2008 Mar; 42(3):255. PubMed ID: 18389566
    [No Abstract]   [Full Text] [Related]  

  • 16. Prescribing of venlafaxine and dosulepin in primary care.
    McAllister-Williams RH; Foran K; Forrest S; Ingram G; McMahon L; Taylor M; Rajwal MS; Cornwall PL
    J Psychopharmacol; 2006 Nov; 20(6):868. PubMed ID: 17060347
    [No Abstract]   [Full Text] [Related]  

  • 17. [Hypomania/mania induced by cessation of antidepressant drugs].
    Kora K; Kaplan P
    Turk Psikiyatri Derg; 2008; 19(3):329-33. PubMed ID: 18791886
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy, safety, and tolerability of fixed-dose desvenlafaxine 50 and 100 mg/day for major depressive disorder in a placebo-controlled trial.
    Boyer P; Montgomery S; Lepola U; Germain JM; Brisard C; Ganguly R; Padmanabhan SK; Tourian KA
    Int Clin Psychopharmacol; 2008 Sep; 23(5):243-53. PubMed ID: 18703933
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of open-label venlafaxine in subjects with major depressive disorder: associations with neuroendocrine response to serotonergic and noradrenergic probes.
    Grossman R; Reynolds D; Goodman M; New A; Silverman J; Schmeidler J; Mitropoulou V; Siever LJ
    Psychiatry Res; 2004 Sep; 128(2):203-6. PubMed ID: 15488964
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Using psychostimulants for treating residual symptoms in major depression.
    Berlim MT; Turecki MG
    J Psychiatry Neurosci; 2007 Jul; 32(4):304. PubMed ID: 17653297
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.